Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

526
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
526
Cardiomyopathy VI: Nursing Management01:29

Cardiomyopathy VI: Nursing Management

365
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...
365
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

470
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
470
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

587
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
587
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

589
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
589
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

619
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
619

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intradialytic Renal Rehabilitation and Mortality: Results from the Registry of Active Renal Rehabilitation in Dialysis Patients (REVEAL-D).

Clinical journal of the American Society of Nephrology : CJASN·2026
Same author

Randomized Trial of Finerenone on Urinary Albumin-to-Creatinine Ratio in Type 2 Diabetes Mellitus and CKD.

Kidney international reports·2026
Same author

Relevant Adverse Events and Drug Discontinuation of Sacubitril/Valsartan in Patients with Transthyretin Amyloid Cardiomyopathy - Insights from the REVIEW-HF Registry.

International heart journal·2026
Same author

Dynamic functional connectivity in borderline personality disorder: associations with trauma, emotion regulation and symptom severity.

European archives of psychiatry and clinical neuroscience·2026
Same author

Prognostic Value of In-Hospital Nutritional Status Improvement in Heart Failure: Insights From JROADHF-NEXT Registry.

Global heart·2026
Same author

The impact of country income level on the management of heart failure with preserved ejection fraction: an international survey.

ESC heart failure·2026

Related Experiment Video

Updated: Feb 13, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

Takotsubo cardiomyopathy.

Keisuke Kida1, Yoshihiro J Akashi, Giovanni Fazio

  • 1Division of Cardiology, Department of Internal Medicine, St. Marianna University School of Medicine 2-16-1 Sugao Miyamae, Kawasaki, Japan. heart-kida@marianna-u.ac.jp

Current Pharmaceutical Design
|July 17, 2010
PubMed
Summary

Takotsubo cardiomyopathy, a stress-induced heart condition, lacks global diagnostic guidelines. This review synthesizes current research on its diagnosis, mechanisms, and treatment, aiding understanding of this syndrome.

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.4K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

Related Experiment Videos

Last Updated: Feb 13, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.4K
Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine
10:08

Tachycardia-Induced Cardiomyopathy As a Chronic Heart Failure Model in Swine

Published on: February 17, 2018

14.0K

Area of Science:

  • Cardiology
  • Internal Medicine

Background:

  • Takotsubo cardiomyopathy (TTC) was first identified in Japan in 1990.
  • Worldwide publications on TTC, including atypical presentations, have increased.
  • There is a lack of global consensus on diagnostic criteria and treatment guidelines for TTC.

Purpose of the Study:

  • To summarize current case reports and reviews on Takotsubo cardiomyopathy.
  • To establish a deeper understanding of the syndrome's diagnosis, cardiac biomarkers, electrocardiogram, cardiac imaging, mechanism, treatment, and prognosis.

Main Methods:

  • Literature review of case reports and reviews on Takotsubo cardiomyopathy.
  • Synthesis of information regarding diagnostic criteria, biomarkers, ECG, imaging, mechanisms, treatment, and prognosis.

Main Results:

  • Takotsubo cardiomyopathy diagnosis and treatment lack worldwide consensus.
  • Catecholamine cardiotoxicity is a suspected key mechanism.
  • Atypical presentations and incidental coronary artery disease are increasingly reported.

Conclusions:

  • Further research is needed to elucidate the exact mechanisms of Takotsubo cardiomyopathy.
  • Development of global guidelines for diagnosis and treatment is essential.
  • A comprehensive understanding of TTC is crucial for effective patient management.